NCT04355728

Use of UC-MSCs for COVID-19 Patients

Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Camillo Ricordi · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS).

Conditions

• Corona Virus Infection
• ARDS
• ARDS, Human
• Acute Respiratory Distress Syndrome
• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.	UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
OTHER	Vehicle + Heparin along with best supportive care	Best supportive care treatment per the treating hospital protocol.

Timeline

• Start date: 2020-04-25
• Primary completion: 2020-10-31
• Completion: 2020-10-31
• First posted: 2020-04-21
• Last updated: 2021-12-06
• Results posted: 2021-12-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study